NCT03261739View on ClinicalTrials.gov

Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

August 28, 2017

Primary Completion Date

August 24, 2018

Study Completion Date

August 24, 2018

Conditions
NAFLD
Interventions
BIOLOGICAL

RYI-018

Anti-CB1 monoclonal antibody

BIOLOGICAL

Placebo

Placebo

Trial Locations (6)

6009

BRB Site, Nedlands

32804

BRB Site, Orlando

33147

BRB Site, Miami

78215

BRB Site, San Antonio

91911

BRB Site, Chula Vista

M4G 3E8

BRB Site, Toronto

Sponsors

Collaborators (1)

ProSciento, Inc.
All Listed Sponsors
collaborator

ProSciento, Inc.

INDUSTRY

collaborator

Perspectum

INDUSTRY

lead

Bird Rock Bio, Inc.

INDUSTRY